Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Procyon Biopharma Inc. -- Ignore unavailable to you. Want to Upgrade?

To: thebeach who wrote (333)	5/19/2002 6:58:47 PM
From: thebeach	Read Replies (1) \| Respond to of 356

I must agree with the general consensus on this board. Procyon will be one of the hottest biotech stories of 2002. I ask each of you - who follow many of Canada's leading biotech companies to compare the product pipelines and licensing execution that Procyon management has demonstrated. The stock is clearly undervalued with a market-cap of $70 million. The Phase II and III trials that FIBROSTAT is going through alone must be worth several hundred million. These trials are all funded by Biovail - standard licensing deal. Look at three things: (1) Management's ability to execute - i.e: already licensed two products to two major pharmaceutical companies; (2) Option agreement with CHIRON on PSP Antibody - MASSIVE product posssibility; and (3) Their DEEP cancer product pipeline (both PSP and ANA). This is one of those hidden diamonds in the rough. Great management, great story, deep pipeline = higher share price. Advertisement: